PTJ
TTPH

Paul Tudor Jones’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Paul Tudor Jones’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,000
Closed -$684K – 1370
2017
Q3 		$684K Buy
+5,000
New +$669K 0.02% 538
2017
Q2 		– Sell
-560
Closed -$103K – 1505
2017
Q1 		$103K Sell
560
-361
-39% -$40.5K ﹤0.01% 1299
2016
Q4 		$74K Buy
921
+107
+13% +$8.46K ﹤0.01% 1322
2016
Q3 		$62K Buy
814
+56
+7% +$4.49K ﹤0.01% 1366
2016
Q2 		$65K Sell
758
-1,460
-66% -$134K ﹤0.01% 1543
2016
Q1 		$205K Buy
2,218
+1,093
+97% +$109K 0.01% 1500
2015
Q4 		$226K Sell
1,125
-3,605
-76% -$719K 0.01% 1382
2015
Q3 		$706K Buy
+4,730
New +$3.47M 0.02% 563
2014
Q1 		– Sell
-500
Closed -$135K – 1482
2013
Q4 		$135K Buy
+500
New +$119K 0.01% 1172

Other funds holding TTPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's TTPH Position: Q4 2017 in Review

Paul Tudor Jones sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2017, closing a stake of 5,000 shares — an estimated $684K sold.

Paul Tudor Jones first reported a position in TTPH in Q4 2013 and held it in 9 quarters. The position peaked at $706K in Q3 2015. 103 funds tracked by Wall St. Rank hold TTPH as of Q4 2017.

  • Paul Tudor Jones reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 5,000 Tetraphase Pharmaceuticals, Inc. shares in Q4 2017, an estimated $684K.
  • Paul Tudor Jones first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 9 quarters.
  • Paul Tudor Jones's Tetraphase Pharmaceuticals, Inc. position peaked at $706K in Q3 2015.
  • 103 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2017.

Based on Tudor Investment Corp's 13F filing for Q4 2017, filed 14 Feb 2018.